Latest: The need for reproducible and standardized metrics for SARS-CoV-2: What we learned from...
Latest: Immuno-oncology: Explore the future of cancer therapy
Latest: From tiny particles to big success: KNAUER awarded the Innovation Prize for Berlin...
Latest: MOBILion Systems rolls out red carpet for MOBIE at hometown American Society for Mass...
Latest: ‘Challenges are easier to overcome if you collaborate’
Latest: Seamless food and beverage testing: There’s an app for that
Latest: LevitasBio announces new approaches to sample preparation and cell enrichment
The need for reproducible and standardized metrics for SARS-CoV-2: What we learned from COVID-19
‘Lab product reviews are an invaluable companion to my research’
Moderna edges out Pfizer vaccine in head-to-head comparison
New study predicts how SARS-CoV-2 evades vaccines
5 top trending videos on cell culture studies
5 upcoming webinars to accelerate your research
A guide to efficient and greener cannabinoid purification
Increasing LC-MS accessibility for streamlined biotherapeutic analysis
Increased sample throughput for organochlorine pesticides analysis
Flexible sample management for life science laboratories
eLabJournal: More than just an electronic notebook
Immtox 270 Brochure
Biophysical Characterization Technology
How to buy next-generation sequencing
Virtual Clinical Science Summit
Virtual Cancer & Immunology Research Summit
05 Feb 22 - 09 Feb 22
Analytical Science Summit...
14 Feb 22 - 15 Feb 22
NEW: Infectious Disease &...
01 Mar 22 - 07 Mar 22
04 Apr 22 - 08 Apr 22
09 May 22 - 13 May 22
Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have provided an update on the MOVe-OUT study of molnupiravir (MK-4482, EIDD-2801), an investi...Read Full ArticleDiane Li